CLINICAL TRIALS AND OBSERVATIONS A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
نویسندگان
چکیده
Jean-Luc Harousseau,1 Giovanni Martinelli,2 Wieslaw W. Jedrzejczak,3 Joseph M. Brandwein,4 Dominique Bordessoule,5 Tamas Masszi,6 Gert J. Ossenkoppele,7 Julia A. Alexeeva,8 Gernot Beutel,9 Johan Maertens,10 Maria-Belen Vidriales,11 Hervé Dombret,12 Xavier Thomas,13 Alan K. Burnett,14 Tadeusz Robak,15 Nuriet K. Khuageva,16 Anatoly K. Golenkov,17 Elena Tothova,18 Lars Mollgard,19 Youn C. Park,20 Annick Bessems,20 Peter De Porre,20 and Angela J. Howes,20 for the FIGHT-AML-301 Investigators
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
In an attempt to improve induction chemotherapy for older patients with acute myeloid leukemia (AML),1314 patients were randomized to 1 of 3 induction treatments for 2 courses of DAT (daunorubicin, cytarabine, and thioguanine) 3 1 10, ADE (daunorubicin, cytarabine, and etoposide) 10 1 3 1 5, or MAC (mitoxantronecytarabine). The remission rate in the DAT arm was significantly better than ADE (62...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
The median age at the time of diagnosis of acute myeloid leukemia (AML) in the United States is 68 years. With increasing age, the response rates to standard chemotherapy decrease and early mortality increases. Data from 5 SWOG trials show that the complete response (CR) rates to chemotherapy-based treatment regimens fall from 65% for patients,56 years of age to 46%, 39%, and 33% with each addi...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
Older patients with acute myeloid leukemia (AML) have limited treatment options and a poor prognosis, thereby warranting novel therapeutic strategies. We evaluated the efficacy of lenalidomide as frontline therapy for older AML patients. In this phase 2 study, patients 60 years of age or older with untreated AML received highdose (HD) lenalidomide at 50 mg daily for up to 2 28-day cycles. If pa...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
The primary objective of this phase 3 study was to determine whether postconsolidation immunotherapy with interleukin-2 (IL-2) and histamine dihydrochloride (HDC) improved the leukemia-free survival (LFS) of adult patients with acute myeloid leukemia (AML) in complete remission (CR). Three hundred twenty patients with AML (median age, 57 years; range, 18-84 years) were stratified by CR1 or subs...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group
We investigated the relative prognostic significance of cytogenetics in 635 adult acute myeloid leukemia (AML) patients 60 years of age or older treated on front-line protocols. Classification trees and treestructured survival analysis (TSSA) were used to identify important cytogenetic groups, and their prognostic significance was then assessed in multivariable analysis (MVA). Overall, 48.5% ac...
متن کامل